Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

20141,598 citationsJournal Articlebronze Open Access

Authors

Éric Pujade-Lauraine · Université Paris Cité

Felix Hilpert · Université Paris Cité

B. Weber · Université Paris Cité

Alexander Reuß · Université Paris Cité

Andrés Poveda · Université Paris Cité

Gunnar B. Kristensen · Université Paris Cité

Roberto Sorio ·

Abstract

Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant. No new safety signals were observed.

Topics & Keywords

Ovarian cancer diagnosis and treatment Intraperitoneal and Appendiceal Malignancies Cancer Mechanisms and Therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 32, Issue 13, pp. 1302-1308

DOI: 10.1200/jco.2013.51.4489

Field-Weighted Citation Impact: 179.30